Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Kevin Gaffney
Assistant Research Professor, Pharmacology - (Research Series Track)
Pharmacology
Full Page
Overview
Research
More
Collaboration
(11)
Bonnie LaFleur
Mutual work: 2 Grants﹒2 Proposals
Collaboration Details
Todd Vanderah
Mutual work: 1 Proposal
Collaboration Details
Elsa Reyes Reyes
Mutual work: 1 Grant
Collaboration Details
Roberta Brinton
Mutual work: 2 Grants﹒6 Proposals
Collaboration Details
Theodore Trouard
Mutual work: 1 Grant﹒2 Proposals
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(5)
Biomarker Development for the Evaluation of Mas Agonist, RASRx1902, in Amyotrophic Lateral Sclerosis
Active
·
2022
·
$152.1K / $1.5M
·
External
Co-Investigator (COI)
biomarker development,
mas agonist,
rasrx1902,
amyotrophic lateral sclerosis,
evaluation
IND Enabling Studies for RASRx 1902, a Novel Mas Receptor Agonist, for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease
Active
·
2020
·
$1.5M / $6.5M
·
External
Co-Investigator (COI)
alzheimer's disease,
cognitive impairment,
mas receptor agonist,
ind enabling studies,
rasrx1902
Therapeutic Idea for the Treatment of ALS with RASRx1902
2019
·
$89.4K / $893.6K
·
External
Co-Investigator (COI)
als treatment,
therapeutic,
rasrx1902,
neurodegenerative diseases,
drug development
Arizona Alzheimer's Consortium Match Projects
2019
·
$18K / $300K
·
External
Co-Investigator (COI)
alzheimer's research,
consortium collaboration,
arizona initiatives,
medical research,
dementia studies
Arizona Alzheimer's Consortium Match Projects
2018
·
$15K / $300K
·
External
Co-Investigator (COI)
alzheimer's,
consortium,
arizona,
match,
projects
Publications
(19)
Recent
Mitigation of cognitive decline and brain pathology after transaortic constriction by Mas agonists
2021
cognitive decline,
brain pathology,
mas agonists,
transaortic constriction,
mitigation
P1‐085: MAS AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE
2019
neurodegenerative disease,
agonists,
treatment,
mas,
research
Improving the innate immune response in diabetes by modifying the renin angiotensin system
2019
diabetes,
innate immune,
renin-angiotensin system,
immune response,
modification
A(1-7) reduces pathologies associated with SLE in MRL-lpr mice
2018
autoimmunity,
immunology,
mice models,
pathology,
drug development
Development of angiotensin II 1-7) analog as an oral therapeutic for the treatment of chemotherapy-induced myelosuppression
2018
chemotherapy-induced myelosuppression,
angiotensin ii 1-7 analog,
oral therapeutic,
development,
treatment
Methods, compounds, and compositions for the treatment of musculoskeletal diseases
2018
musculoskeletal diseases,
treatment methods,
compounds,
compositions,
medical research
Methods, compounds, and compositions for the treatment of angiotensin-related diseases
2017
drug development,
angiotensin,
therapeutic compounds,
disease treatment,
medical research
Evaluation of MMX1902 as an Oral Treatment for Duchenne Muscular Dystrophy
2016
drug efficacy,
duchenne muscular dystrophy,
clinical trial,
oral administration,
drug development
Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols.
2015
molecular biology,
chemistry,
pharmacology,
biochemistry,
polyphenols
Abstract 1811: Evaluation of anti-CXCR2 small molecule inhibitors as novel chemotherapy targeting the Interleukin-8 pathway in colorectal cancer
2014
chemotherapy,
colorectal cancer,
small molecule inhibitors,
interleukin-8 pathway,
cxcr2 inhibitors
